Medical/Pharmaceuticals
I-Mab Announces Acceptance of IND Application from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors
SHANGHAI and GAITHERSBURG, Md., Sept. 28, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the Center for Drug Evaluation (CDE) of China Nati...
2021-09-28 20:00
4738
Xiaobai Maimai Plans to Enter the U.S. Radiation Oncology Services Market
BEIJING, Sept. 28, 2021 /PRNewswire/ -- Xiaobai Maimai Inc. (NASDAQ: HX) ("Xiaobai Maimai", the "Company", or "we"), a social e-commerce platform in China, today announced that it plans to enter the radiation oncology services market in the U.S. The Company recently established We Health Limited...
2021-09-28 19:00
8589
University Health Network (UHN) Selects Kailo Medical's SonoReview
Quality Improvement via Automated Structured Reporting CALGARY, AB, Sept. 27, 2021 /PRNewswire/ -- Kailo Medical, a leader in medical imaging workflow solutions, today announced that the University Health Network (UHN), a group ofOntario hospitals including Toronto General, Princess Margaret, T...
2021-09-27 21:30
1647
Harbour BioMed Announces Dosing of First Patient of Batoclimab Phase III Trial in Patients with Generalized Myasthenia Gravis
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Sept. 27, 2021 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) announced that, the clinical trial of its anti-FcRn antibody, batoclimab (HBM9161), has completed the first dosing of first patient in registrational phase III trial f...
2021-09-27 21:03
5326
CGBIO to introduce AI-empowered robotic intervention device, with clinical trials
* CGBIO, NDR Medical Technology, forge a partnership in a move to introduce puncture robot technology and collaborate in clinical studies. * CGBIO expects this partnership to gain its stronger competitiveness in the global digital healthcare market beyond the presence as a pioneer of AI based ...
2021-09-27 21:00
2403
Bo'ao Winhealth Rare Disease Medical Center and Ali Health Jointly Launched the "Global Drug Information Platform for Rare Diseases"
BEJING, Sept. 27, 2021 /PRNewswire/ -- On September 25, 2021 in Beijing, China, the "Global Drug Information Platform for Rare Diseases" was successfully kicked off at Ali Center inBeijing. Jointly built by Bo'ao Winhealth Rare Disease Medical Center and Ali Health, the Platform aims at addressin...
2021-09-27 21:00
3959
Immunoforge Inc. receives U.S. FDA ODD for Treatment of Polymyositis
SEOUL, South Korea, Sept. 27, 2021 /PRNewswire/ -- Immunoforge (Co-CEOs Sung-min Ahn,Kiho Chang), a company specializing in developing new drugs for rare musculoskeletal diseases, has reported that their new drug candidate PF1801 has received Orphan Drug Designation (ODD) from the U.S. FDA for th...
2021-09-27 21:00
1894
Senhwa Announces Acceptance of Early Positive COVID-19 Phase II Study Abstract for Presentation at the ISIRV-WHO Conference
* Early Positive Phase 2 efficacy and safety data are both statistically significant and clinically meaningful. * No SAE related to Silmitasertib was reported. * Silmitasertib is a host-directed antiviral and an anti-inflammatory investigational therapy expected to be effective against eme...
2021-09-27 19:20
3375
Clever Culture Systems Appoints Thermo Fisher Scientific as Exclusive US APAS® Distributor
ADELAIDE, Australia, Sept. 27, 2021 /PRNewswire/ -- Australian medical technology company LBT Innovations Limited (ASX: LBT) (LBT or the Company), a leader in medical technology automation using artificial intelligence, is pleased to announce the signing of an exclusive Distribution Agreement for...
2021-09-27 16:00
2073
Transcenta Received IND Clearance from NMPA of its Anti-sclerostin Monoclonal Antibody TST002
SUZHOU, China, Sept. 26, 2021 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta"), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that it received IND clearance on...
2021-09-27 08:30
1476
Kintor Pharma Announces Brazil's ANVISA Approves Phase III Clinical Trial of Proxalutamide for the Treatment of Hospitalized COVID-19 Patients
SUZHOU, China, Sept. 26, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that onSeptember 22 the Brazilian Health Regulatory Agency (ANVISA) ...
2021-09-26 23:09
6488
GenScript ProBio and AskGene Enter into a Non-exclusive License of A sdAb Targeting Immune Checkpoint Target
NANJING, China, Sept. 26, 2021 /PRNewswire/ -- On September 26, 2021, GenScript ProBio and AskGene signed a license agreement forGenScript ProBio's single-domain antibody (sdAb) targeting an immune checkpoint target.GenScript ProBio grants a non-exclusive global license to AskGene to use GenScrip...
2021-09-26 22:28
2563
Boan Biotech to Present the Pre-clinical Data of Its Proprietary CD3+ T-cell Engager Platform and CEA/CD3 Bispecific Antibody at World Bispecific Summit
Sept. 25, 2021, BOSTON /PRNewswire/ -- Boan Biotech, a subsidiary of Luye Pharma Group, will orally present the pre-clinical data of its proprietary CD3+ T-cell engager platform and CEA/CD3 bispecific antibody at World Bispecific Summit 2021. The annual World Bispecific Summit aiming to promote ...
2021-09-26 10:12
2503
New Drug Application for Cadonilimab (PD-1/CTLA-4 Bi-Specific Antibody) for the Treatment of Relapsed or Metastatic Cervical Cancer Accepted by NMPA
HONG KONG, Sept. 23, 2021 /PRNewswire/ -- Akeso, Inc. (the Company, 9926.HK) announces that the National Medical Products Administration (the NMPA) ofChina has officially accepted the new drug application for the world's first-in-class Cadonilimab (PD-1/CTLA-4 bi-specific antibody, research and d...
2021-09-24 09:18
4139
Ascentage Pharma's MDM2-p53 Inhibitor Alrizomadlin (APG-115) Granted Fast Track Designation by the US FDA for the Treatment of Relapsed/Refractory Unresectable or Metastatic Melanoma
SUZHOU, China, and ROCKVILLE, MD, Sept 22, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that its novel MDM2-p53 inhibitor alrizomadlin (A...
2021-09-23 07:40
2292
United Imaging Announces FDA Clearance for its Versatile Ultra-Premium Scanner, the uCT® ATLAS
HOUSTON, Sept. 22, 2021 /PRNewswire/ -- United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, announced FDA clearance for the uCT ATLAS, the latest in the company's Computed Tomography (CT) portfolio of scanners and the 25th FDA clearance for the company overall....
2021-09-22 21:00
2336
Clover's COVID-19 Vaccine Candidate Demonstrates 79% Efficacy Against Delta in Global Phase 2/3 SPECTRA Trial Dominated by Variants of Concern and Interest
* Trial enrolled over 30,000 adult & elderly participants across 4 continents; 100% of SARS-CoV-2 strains observed in efficacy analysis were variants (Delta was predominant strain) * Primary and secondary efficacy endpoints were successfully met * 100% efficacy against severe COVID-19 & hosp...
2021-09-22 18:56
2847
Samsung Biologics showcases its newest CDO process platform, S-Cellerate™, at BPI 2021, offering expedited timeline to IND and BLA
INCHEON, South Korea, Sept. 22, 2021 /PRNewswire/ -- Samsung Biologics, a global contract development and manufacturing organization (CDMO), introduced its proprietary technology platform, S-CellerateTM, at the BioProcess International Conference (BPI 2021) to offer clients an integrated and seam...
2021-09-22 18:00
2272
Asieris Appoints Dr. Alice Chen as Vice President, Discovery Biology and Head of Translational Research
SHANGHAI, Sept. 22, 2021 /PRNewswire/ -- Asieris Pharmaceuticals announced the appointment of Dr.Alice Chen as Vice President, Discovery Biology and Head of Translational Research with effect fromSeptember 20, 2021. She will report to Dr.Kevin Pan, Founder and CEO of Asieris. Alice has over 20 ...
2021-09-22 14:45
1544
New Therapy to Treat Advanced Small Cell Lung Cancer ZEPZELCA® (lurbinectedin) Approved in Singapore
Highlights: * ZEPZELCA® (lurbinectedin) is the first new therapy approved in Singapore to treat 2L metastatic small cell lung cancer (SCLC) in 20 years * ZEPZELCA provisional approval represents an important advance for adult patients whose metastatic SCLC has progressed on or after platinum-...
2021-09-22 14:30
2388
Week's Top Stories
Most Reposted
Vietnam Explores Sustainable Aviation Fuel Development at International Conference in Hanoi
[Picked up by 301 media titles]
2026-06-25 14:33
MetaOptics Begins Shipment of Metalens Smartphone and AI Smart Glasses to European and Japanese Customers for Evaluation
[Picked up by 300 media titles]
2026-06-26 18:11IPD and ABB Help Power Sustainable Operations at New Sydney Fish Market
[Picked up by 298 media titles]
2026-06-22 17:40
SPHERE AX Partners with U.S. AI Semiconductor Company Blaize at the National Assembly
[Picked up by 293 media titles]
2026-06-24 18:00
BELLUSTAR TOKYO Ranked No. 10 Among Japan's Best City Hotels in Prestigious Award Chosen by Asia-Pacific Travelers
[Picked up by 290 media titles]
2026-06-24 12:00
Most Read
National Book Store Partners with Anchanto to accelerate success across Online Channels & 260+ Retail Locations
2026-06-23 08:00
2985
IBM and OpenAI Bring Frontier AI to Cyber Defense--Helping Enterprises Keep Pace with Machine-Speed Threats
2026-06-23 05:18
2773
